Abstract:BACKGROUNDCombination of androgen ablation along with early detection and surgery has made prostate cancer highly treatable at the initial stage. However, this cancer remains the second leading cause of cancer death among American men due to castration‐resistant progression, suggesting that novel therapeutic agents are urgently needed for this life‐threatening condition. Phosphatidylinositol 3‐kinase p110β is a major cellular signaling molecule and has been identified as a critical factor in prostate cancer progression. In a recent report, we established a nanomicelle‐based strategy to deliver p110β‐specific inhibitor TGX221 to prostate cancer cells by conjugating the surface of nanomicelles with a RNA aptamer against prostate specific membrane antigen (PSMA) present in all clinical prostate cancers. In this study, we tested this nanomicellar TGX221 for its in vivo anti‐tumor effect in mouse xenograft models.METHODSProstate cancer cell lines LAPC‐4, LNCaP, C4–2 and 22RV1 were used to establish subcutaneous xenograft tumors in nude mice. Paraffin sections from xenograft tumor specimens were used in immunohistochemistry assays to detect AKT phosphorylation, cell proliferation marker Ki67 and proliferating cell nuclear antigen (PCNA), as well as 5‐bromo‐2‐deoxyuridine (BrdU) incorporation. Quantitative PCR assay was conducted to determine prostate‐specific antigen (PSA) gene expression in xenograft tumors.RESULTSAlthough systemic delivery of unconjugated TGX221 significantly reduced xenograft tumor growth in nude mice compared to solvent control, the nanomicellar TGX221 conjugates completely blocked tumor growth of xenografts derived from multiple prostate cancer cell lines. Further analyses revealed that AKT phosphorylation and cell proliferation indexes were dramatically reduced in xenograft tumors received nanomicellar TGX221 compared to xenograft tumors received unconjugated TGX221 treatment. There was no noticeable side effect by gross observation or at microscopic level of organ tissue section.CONCLUSIONThese data strongly suggest that prostate cancer cell‐targeted nanomicellar TGX221 is an effective anti‐cancer agent for prostate cancer. Prostate 75: 593–602, 2015. © 2015 Wiley Periodicals, Inc.

17-DMCHAG, a New Geldanamycin Derivative, Inhibits Prostate Cancer Cells Through Hsp90 Inhibition and Survivin Downregulation

17-Abag, A Novel Geldanamycin Derivative, Inhibits Lncap-Cell Proliferation Through Heat Shock Protein 90 Inhibition

The HSP90 Inhibitor 17-PAG Effectively Inhibits the Proliferation and Migration of Androgen-Independent Prostate Cancer Cells

Design, Synthesis and Biological Evaluation of 17-Arylmethylamine-17-demethoxygeldanamycin Derivatives As Potent Hsp90 Inhibitors

Discovery of Diamine-Linked 17-Aroylamido-17-demethoxygeldanamycins As Potent Hsp90 Inhibitors

Synthesis and Preliminary Antitumor Activity Evaluation of 17-(5-(substituted Cinnamamido)pentylamino)-17-demethoxygeldanamycin Derivatives As Potent Hsp90 Inhibitors

Discovery of novel 17-phenylethylaminegeldanamycin derivatives as potent Hsp90 inhibitors.

In Vitro and in Vivo Evaluation of 17-Phenylpropylamine/phenoxyethylamine-17-demethoxygeldanamycins As Potent Hsp90 Inhibitors

Heat shock protein 90 inhibitor,17-DMAG,suppresses proliferation and induces apoptosis in pancreatic cancer cells in vitro

SNX-25a, a Novel Hsp90 Inhibitor, Inhibited Human Cancer Growth More Potently Than 17-AAG.

Synthesis of Novel 17-[3,6-dioxa-8-n-(substituted Cinnamyol)-Octanediamino]-17-demethoxygeldanamycin Derivatives

Potent Hsp90 Inhibitors with Significant Potential in Cancer Therapy

The Apoptotic Effect and Associated Signalling of Hsp90 Inhibitor 17-Dmag in Hepatocellular Carcinoma Cells

Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin inhibits the proliferation of ARPE-19 cells

Effects of 17-DMAG on Diffuse Large B-cell Lymphoma Cell Apoptosis.

Endoplasmic reticulum stress, autophagic and apoptotic cell death, and immune activation by a natural triterpenoid in human prostate cancer cells

HSP27 Expression Levels Are Associated with the Sensitivity of Hepatocellular Carcinoma Cells to 17-Allylamino-17-demethoxygeldanamycin.

[Effect of Heat Shock Protein 90 Inhibitor 17-Dimethylamino-ethylaminogeldanamycin on TNfalpha-mediated Apoptosis and TNF-induced NF-kappaB Activation].

Study on Geldanamycin of Promoting Heat-Induced Cell Killing of Cervix Cancer HeLa Cells

Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies.

Nanomicellar TGX221 Blocks Xenograft Tumor Growth of Prostate Cancer in Nude Mice